Drug Profile
Adalimumab biosimilar - CinnaGen
Alternative Names: Cinnora®Latest Information Update: 13 Jul 2022
Price :
$50
*
At a glance
- Originator CinnaGen
- Class Anti-inflammatories; Anti-TNF monoclonal antibodies; Antineoplastics; Antipsoriatics; Antirheumatics; Eye disorder therapies; Hepatoprotectants; Immunotherapies; Nootropics; Skin disorder therapies
- Mechanism of Action Immunosuppressants; Tumour necrosis factor alpha inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Rheumatoid arthritis
Most Recent Events
- 18 Feb 2022 No development reported - Phase-III for Rheumatoid arthritis (Adjunctive treatment) in Iran (SC)
- 06 Aug 2017 Cinnagen completes a phase I trial in Healthy volunteers in Iran (NCT03273192)
- 22 Apr 2017 Cinnagen initiates enrolment in a phase I trial in Healthy volunteers in Iran (NCT03273192)